Replies to post #645484 on NorthWest Biotherapeutics Inc (NWBO)

[iclight]

You can't be serious. You spent a lot of posts trying to prove PFS was gonna be a winner.

This you?

Alphapuppy previous musings on primary PFS

My best-educated hypothesis is that clearly, the DCVax-L trial is going to return a positive result on the primary end point

The nice thing about this PFS review also is that there is no crossover effect between the curves such as could occur with my prior overall survival analysis OS.

Remember the preliminary results from 2018?

From that text:

The study’s primary endpoint is PFS, and the secondary endpoint is OS.

Or you could go to the history of the clinicaltrials.gov page for DCvax.

Guess we can toss out your opinion since you don't even remember your own BS.

[exwannabe]

As I recall, the primary endpoint for the original trial prior to any changes was overall survival. Not PFS. A prior trial using only four antigens from IMUC was negative on PFS back and I think 2013 or 2014. so I don’t know why everybody is making such a big deal about the PFS when it wasn’t even the primary endpoint of the original study. They’re like saying it is when it wasn’t.

What total nonsense. Everybody here knows that PFS was always the primary. Who are you even trying to convince with this.?

And you are still diverting from the core issue. That is OS between the trial arms (233 vs 99). Flipper knows it is still key, that is why he is trying to convince people that data is good.

It isn't. if it was LP would be shouting it out.